0.51Open0.51Pre Close0 Volume512 Open Interest22.50Strike Price0.00Turnover89.43%IV22.33%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.51Extrinsic Value100Contract SizeAmericanOptions Type0.2522Delta0.0751Gamma32.71Leverage Ratio-0.0297Theta0.0027Rho8.25Eff Leverage0.0152Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet